Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial

André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Louis Baez-Diaz, Shakir Sarwar, Richard G. Margolese, William B. Farrar, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark